WI-EXACT-SCIENCES-CORP
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage breast cancer involving up to three positive nodes and who have been through the menopause. NICE confirmed that breast cancer patients who are male and trans, non-binary or intersex may benefit from the test depending on their hormonal profile. The recommendation has the potential to impact more than 3000 additional breast-cancer patients in England who will now have access to the test through the National Health Service (NHS).1
The new guidance expands upon earlier NICE recommendations for testing patients without lymph node involvement. Access to genomic testing for patients with lymph node-positive breast cancer addresses the issue of overtreatment with chemotherapy, helping many patients to avoid treatment side effects such as nausea, fatigue, hair loss and potentially secondary cancer. In addition, expanded reimbursement has the potential to free up resources and capacity within NHS breast cancer services.
Dr Caroline Archer, consultant medical oncologist Portsmouth Hospital NHS Trust said: “This is a practice-changing moment for node-positive patients and the NHS. There is an urgent need to target chemotherapy more precisely to those most likely to benefit from it, so that patients can avoid unnecessary side effects. The Oncotype DX Breast Recurrence Score result enables us to do this effectively by providing specific information about an individual’s response to chemotherapy. This positive recommendation marks a significant step forward in supporting equitable access to the test across the country.”
While the majority of patients with lymph node-positive early-stage breast cancer receive chemotherapy, research shows that only a minority benefit from the treatment. The Oncotype DX® test is the only test able to identify around 85% of postmenopausal patients whose cancer outcomes are not likely improved by chemotherapy, meaning they can avoid the risk of side effects.2,3,4
A recent independent UK multi-centre trial led by Prof Holt involving 680 women with lymph node-positive early breast cancer confirmed that using the Oncotype DX test to help guide chemotherapy treatment decisions leads to a substantial reduction in unnecessary chemotherapy, as well as savings for the NHS.5
Prof Simon Holt, Health and Life Science, Swansea University & Peony Breast Care Unit, Prince Philip Hospital said:
“This decision to recommend the use of the Oncotype DX test to guide chemotherapy decisions in early node positive breast cancer will be of great benefit to our postmenopausal patients and to the NHS. The use of the test will reduce the suffering and inconvenience by sparing up to 85% of people unnecessary chemotherapy, which in turn, then reduces the care demands on Oncology services. It also reduces significantly the cost of treatment so that NHS resources can be redistributed to other medical priorities.
Also, our research has shown that the use of the Oncotype DX test means both clinicians and their patients will have much greater confidence in their chemotherapy decisions.”
The test’s efficacy is also supported by the landmark TAILORx6 and RxPONDER7 studies, which demonstrated that most patients with either node-negative or node-positive early-stage breast cancer do not benefit from chemotherapy and can be reliably identified using the Oncotype DX test.
Matt Bull, Head of Northern Europe (UK, Ireland and Nordics) at Exact Sciences, added: “We are delighted that more patients with node-positive breast cancer will now also benefit from knowing their Recurrence Score® result. We are proud of the potential impact the expanded use of the Oncotype DX test will have — better patient treatment, improved clinical confidence and less pressure on the health service.”
About the Oncotype DX Breast Recurrence Score test
The Oncotype DX Breast Recurrence Score test is designed to facilitate personalised clinical decisions by providing information about the biology of an individual breast cancer, with the potential to deliver financial benefits for healthcare systems. The test was first made available to patients in 2004, and over 1,5 million patients around the world have benefited from it. It is incorporated in major breast cancer treatment guidelines, including those of the European Society for Medical Oncology (ESMO) and the St. Gallen International Breast Cancer Conference, as well as the American Society of Clinical Oncology (ASCO®) and the National Comprehensive Cancer Network (NCCN®) in the U.S.
To learn more about the test, visit: https://www.oncotypeiq.com/en
About Exact Sciences
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit https://www.exactsciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation. All other trademarks and service marks are the property of their respective owners.
1 Tumour profiling tests to guide adjuvant chemotherapy decisions for lymph node-positive early breast cancer [DG58], NICE Resource impact tool, May 2024: https://www.nice.org.uk/guidance/dg58/resources/resource-impact-template-excel-13425543901
2 Bello et al. Ann Surg Oncol. 2018.
3 Zhang et al. Breast Can Res Treat. 2020.
4 Stemmer et al. npj Breast Cancer. 2017.
5 Holt et al. British Journal of Cancer, 2024 pp. 1-8
6 Sparano et al. N Engl J Med. 2018
7 Kalinsky et al. New Engl J Med. 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510861568/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release
CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 15:00:00 CET | Press release
Advanced fraud prevention, multi-layered verification and innovative data-driven security solutions are core to Experian’s Ascend Platform™ Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, Presid
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 14:12:00 CET | Press release
Digital payments veteran Rachelle Alexis Lim now spearheads MultiSafepay’s operational strategy as it brings its innovative omnichannel payment platform to businesses of all sizes across Europe, driving inclusive growth for SMEs. Founder, Olaf Geurs, who has led MultiSafepay for nearly three decades will remain Chief Technology Officer and hold his position on the board of directors. In this role he will remain instrumental to driving innovation. Since the start of its strategic partnership with global payment and digitisation provider Antom, MultiSafepay's transaction volume has nearly doubled, and its merchant base has increased by over a quarter. MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie7.11.2025 13:30:00 CET | Press release
Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging effortsPositions Organon for future investment in growth opportunities with a focus on women’s health biopharma and other strategic prioritiesLaborie’s capabilities in medical technology will facilitate broader access to JADA for more mothers Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom